News Archive

2021

April

Media Release / Apr 16, 2021

Kesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMS

Read More
Media Release / Apr 16, 2021

Novartis presents data at AAN on novel combination biomarker that may predict disability worsening in secondary progressive multiple sclerosis

Read More
Media Release / Apr 12, 2021

Novartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients

Read More

March

Media Release / Mar 17, 2021

Novartis awards $450,000 to eight nonprofit organizations through the STEP Program™

Read More

February

Media Release / Feb 16, 2021

Novartis Entresto® granted expanded indication in chronic heart failure by FDA

Read More

January

Media Release / Jan 15, 2021

Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic idiopathic urticaria (CIU)

Read More
2020

May

Media Release / May 27, 2020

Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease

Read More
Media Release / May 06, 2020

Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14

Read More

December

Media Release / Dec 15, 2020

Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF

Read More

Related Links